@ARTICLE{Rajabi, author = {Hosseini, Seyed Alireza and Rajabi, Fatemeh and Akbari Sari, Ali and Ayati, Mohsen and Heidari, Saeed and Ghamary, Fawzieh and }, title = {Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis}, volume = {30}, number = {1}, abstract ={Background: Hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. We performed a systematic review to compare safety, efficacy and effectiveness of degarelix, a new gonadotropin-releasing hormone (GnRH) antagonist (blocker), versus gonadotropin-releasing hormone (GnRH) agonists. Methods: MEDLINE, Web of Science and the Cochrane library were searched to identify all of the published Randomized Controlled Trials (RCTs) that used degarelix versus gonadotropin-releasing hormone agonists with or without anti-androgen therapy for the treatment of prostate cancer. We performed meta-analysis of extracted data on safety and efficacy of the target medication. Results: Six studies were included. They involved a total of 2296 patients which were used in the meta-analysis. Follow-up times after treatment were between 12 weeks and 12 months. Three of six RCTs compared degarelix with goserelin and the others compared it with leuprolide.Meta-analysis on safety outcomes revealed that the only statistically significant difference between the degarelix treated group and GnRH agonists treated group was complication in the injection site which was higher in degarelix-treated group (OR= 46.34, 95% CI: 15.79 to 136, p }, URL = {http://mjiri.iums.ac.ir/article-1-3438-en.html}, eprint = {http://mjiri.iums.ac.ir/article-1-3438-en.pdf}, journal = {Medical Journal of the Islamic Republic Of Iran}, doi = {}, year = {2016} }